GSK投資(zi)1.3億(yi)新元(yuan)在新(xin)加(jia)坡(po)創(chuang)建(jian)了制藥生(sheng)產設(she)施

● GSK opens new state-of-the-art pharmaceutical manufacturing facilities worth $130m in Singapore. Opening of continuous manufacturing facilities and expansion of production building will boost capabilities to accelerate the supply of new breakthrough medicines to patients globally.

葛蘭(lan)素(su)史克(ke)投資(zi)1.3億(yi)新元(yuan)在新(xin)加(jia)坡(po)創(chuang)建(jian)了進的(de)制(zhi)藥生(sheng)產設(she)施。連(lian)續生(sheng)產設(she)施的(de)建(jian)設(she)和(he)生(sheng)產能(neng)力(li)的(de)擴大(da)將加(jia)速(su)新(xin)的(de)突(tu)破(po)性(xing)藥品(pin)的(de)供應。

● One of the new continuous manufacturing facilities is part of Jurong's R&D Pilot Plant and will strengthen the site's capability in drug manufacture by allowing faster production of APIs (Active Pharmaceutical Ingredients) for clinical trials. The first New Chemical Entity (NCE) to be developed at the new facility will be Daprodustat, a new oral treatment for anaemia associated with chronic kidney disease. The new manufacturing process is expected to reduce production time of Daprodustat, enabling faster access to this medicine for patients globally.

其(qi)中壹個(ge)新的(de)連(lian)續生(sheng)產設(she)施是研發(fa)中試(shi)工(gong)廠(chang)，該中(zhong)試(shi)工(gong)廠(chang)將加(jia)快(kuai)原料(liao)藥API（活(huo)性(xing)藥物(wu)）生(sheng)產能(neng)力(li)來用於(yu)臨床(chuang)試(shi)驗(yan)。在新設(she)施開發的(de)個(ge)藥物(wu)將(jiang)是Daprodustat（達布羅達特），壹種(zhong)新的(de)口(kou)服(fu)治(zhi)療與慢性(xing)腎病相(xiang)關的(de)貧血(xue)的(de)藥物(wu)。新(xin)的(de)制(zhi)造工(gong)藝(yi)預計將縮短達(da)布羅達特的(de)生(sheng)產時(shi)間，從(cong)而(er)加(jia)快(kuai)為(wei)患者(zhe)提(ti)供這種(zhong)藥物(wu)的(de)速(su)度(du)。

● The expansion of the production building which makes APIs for HIV medicines will strengthen GSK's capability to produce Dolutegravir, a key GSK asset for HIV treatment. The investment has enabled the renewal of critical infrastructure in the production building and has allowed GSK to test and develop digital technologies in the manufacturing process to drive productivity improvement.

現(xian)有(you)廠(chang)房的(de)擴建將(jiang)擴大(da)生(sheng)產制(zhi)造DoluteGravir的(de)能(neng)力(li)， DoluteGravir是GSK的(de)關(guan)鍵(jian)資(zi)產，用(yong)於(yu)HIV治療。投資(zi)使關(guan)鍵(jian)生(sheng)產車(che)間的(de)基(ji)礎設施得(de)到進壹步提(ti)升(sheng)，並允(yun)許(xu)GSK測試(shi)和(he)開發制(zhi)造過(guo)程(cheng)更加(jia)數(shu)字(zi)化(hua)以(yi)推(tui)動和(he)提(ti)高(gao)生(sheng)產力(li)。

● The investment demonstrates GSK's commitment to Singapore as a key manufacturing and supply site for GSK's global pharmaceutical business and a testbed for advanced manufacturing technology. The investment behind the new facilities is part of the GSK-EDB 10-year Singapore Manufacturing Roadmap.

這筆(bi)投資(zi)表明(ming)，GSK致(zhi)力(li)於(yu)將新(xin)加(jia)坡(po)打造成(cheng)GSK制(zhi)藥業務(wu)的(de)關(guan)鍵(jian)生(sheng)產、供應基(ji)地以(yi)及試(shi)驗(yan)中心(xin)。投資(zi)新工(gong)廠(chang)是GSK-EDB 十(shi)年新加(jia)坡(po)制(zhi)造藍(lan)圖中的(de)壹部(bu)分。

● Regis Simard, President Pharmaceuticals Supply Chain, GSK said, "As one of the most innovative cities in the world, Singapore is home to an ecosystem of companies and organisations that are creating and exporting innovative solutions. Innovation is at the heart of GSK, we are glad to invest in scientific and technical excellence in Singapore to develop and launch the next generation of products which meet the needs of patients, payers and consumers."

GSK制藥供應鏈總裁雷吉(ji)斯·西(xi)馬爾說： “作(zuo)為(wei)壹個(ge)在世界(jie)上有(you)創(chuang)新(xin)精(jing)神(shen)的(de)城市(shi)，新(xin)加(jia)坡(po)有(you)著(zhe)良好的(de)生(sheng)態系(xi)統(tong)，是(shi)出(chu)口創新(xin)產(chan)品(pin)的(de)公(gong)司(si)和(he)機(ji)構(gou)的(de)發(fa)源(yuan)地(di)。創(chuang)新是GSK的(de)核心(xin)，我(wo)們很(hen)高(gao)興(xing)在新(xin)加(jia)坡(po)投資(zi)來發展(zhan)和(he)推(tui)出(chu)下(xia)壹代(dai)新產品(pin)，滿(man)足(zu)患者(zhe)和(he)消費(fei)者(zhe)。”

● Lim Hock Heng, Vice President & Site Director, Pharmaceuticals Supply Chain Singapore, GSK said, "Advanced manufacturing systems are pivotal for GSK to stay at the forefront of the pharmaceutical manufacturing sector. Further investment in digital manufacturing operations and processes will allow GSK to ensure efficient and high-quality production of our medicines."

Lim Hock Heng，GSK新(xin)加(jia)坡(po)藥品(pin)供應副(fu)總裁兼地方(fang)總監(jian)說，“先進(jin)的(de)制(zhi)造系(xi)統(tong)是(shi)使葛蘭(lan)素(su)史克(ke)保持在制藥行業的(de)地(di)位(wei)的(de)關(guan)鍵(jian)。對(dui)數字制造業務(wu)和(he)流(liu)程的(de)進(jin)壹步投資(zi)將允(yun)許(xu)GSK確(que)保藥品(pin)的(de)生(sheng)產效(xiao)率和(he)高品(pin)質(zhi)。

● Chng Kai Fong, Managing Director, EDB said, "Over the years, GSK has continually partnered with Singapore to develop advanced manufacturing technologies, such as continuous manufacturing and digital manufacturing. They have also been a strong partner in training our local talent. These efforts have supported the growth of the industry as a whole and in turn has created diverse and attractive job opportunities for Singapore."

EDB董(dong)事(shi)總(zong)經理(li)Chng Kai-fong說：“多年來，GSK不斷與新(xin)加(jia)坡(po)合(he)作(zuo)，發(fa)展(zhan)先(xian)*進制(zhi)造業技(ji)術，如連(lian)續制造和(he)數字(zi)制造。他(ta)們在(zai)培訓(xun)本地(di)人才(cai)方(fang)面(mian)也(ye)是(shi)壹個(ge)強(qiang)有(you)力(li)的(de)合(he)作(zuo)夥伴(ban)。這些(xie)努(nu)力(li)支持了整(zheng)個(ge)行業的(de)發(fa)展(zhan)，從(cong)而創(chuang)造了新加(jia)坡(po)的(de)就(jiu)業機(ji)會(hui)多樣化和(he)吸引(yin)力(li)。”

● About GSK-EDB 10-year Singapore Manufacturing Roadmap：In 2012, GSK and Singapore's Economic Development Board (EDB) jointly explored strategic investment options for GSK in Singapore that would be beneficial for both parties as part of their long-standing collaborative relationship. This led to the formation of a GSK-EDB 10-year Singapore Manufacturing Roadmap that aims to guide the investment decisions and developmental work to ensure manufacturing remains a competitive edge for both GSK and Singapore. This announcement is one of the collaborative areas in this 10-year roadmap.

關於(yu)GSK-EDB 十年新加(jia)坡(po)制(zhi)造藍(lan)圖：2012年，GSK與新(xin)加(jia)坡(po)經(jing)濟(ji)發展(zhan)委員(yuan)會(hui)（EDB）聯合(he)，把(ba)探索(suo)新加(jia)坡(po)GSK的(de)戰略(lve)投資(zi)選擇(ze)作(zuo)為(wei)對(dui)雙(shuang)方都(dou)有(you)利(li)的(de)長期(qi)合(he)作(zuo)的(de)壹部(bu)分。這就(jiu)形成了GSK-EDB十年新加(jia)坡(po)制(zhi)造藍(lan)圖。旨在(zai)指導投資(zi)決(jue)策和(he)開發工(gong)作(zuo)，以(yi)確(que)保GSK和(he)新加(jia)坡(po)在(zai)連(lian)續制造業上的(de)競爭優勢。

● About Continuous manufacturing：

Continuous manufacturing requires far fewer manual interventions than the traditional 'batch production' in which each stage of the production process takes place sequentially. It enables production to be quicker and at good quality standards. The flexible nature of the production process means that the volume of API produced can be adapted according to demand. There are also a number of environmental benefits from this technique, which will help to reduce the site's carbon footprint.

關(guan)於(yu)連(lian)續制造：連(lian)續制造所(suo)需(xu)的(de)人(ren)工(gong)幹(gan)預遠(yuan)遠少(shao)於(yu)傳統(tong)的(de)“批(pi)量生(sheng)產”，生(sheng)產的(de)每(mei)個(ge)階(jie)段(duan)過程按(an)順(shun)序進(jin)行。它(ta)可(ke)以(yi)提(ti)高(gao)生(sheng)產速(su)度(du)和(he)產品(pin)質(zhi)量，且(qie)生(sheng)產過(guo)程更(geng)加(jia)靈活(huo)。生(sheng)產過(guo)程的(de)靈活(huo)性意(yi)味(wei)著(zhe)生(sheng)產的(de)原料(liao)藥的(de)量可(ke)以(yi)根(gen)據需(xu)要進行調(tiao)整(zheng)。有(you)此(ci)外，這項(xiang)技(ji)術還(hai)帶(dai)來了許多環境效(xiao)益(yi)，這將(jiang)有(you)助(zhu)於(yu)減少(shao)當地(di)的(de)碳(tan)排(pai)放(fang)。

● About GSK : GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

關於(yu)葛蘭(lan)素(su)史克(ke): GSK是壹家以(yi)科(ke)學(xue)為(wei)主(zhu)導的(de)醫(yi)療保健公(gong)司(si)，其(qi)特殊目(mu)的(de)是(shi)：幫(bang)助(zhu)人們(men)做(zuo)得(de)更多，感(gan)覺更(geng)好，活(huo)得(de)更長。

● About GSK's Jurong Site, Singapore：GSK's Jurong site was opened in 1982. The site, which now sits on a nine-hectare site, has evolved from bulk manufacture of established products in the early days to becoming a leading New Product Introductions (NPI) site within the GSK pharma supply chain.  It is focused on the development of late phase New Chemical Entities (NCEs) and delivering higher value products such as very active compounds in small batch sizes. The site currently has an R&D Pilot Plant where NCEs are developed and scaled up, and three production buildings making 13 Active Pharmaceutical Ingredients for a range of medicines prescribed for the treatment of respiratory, oncology, allergy, anti-viral and neurological conditions. There are about 490 employees working at the Jurong site.

關(guan)於(yu)GSK新加(jia)坡(po)Jurong：葛(ge)蘭(lan)素(su)史克(ke)在新(xin)加(jia)坡(po)的(de)Jurong設(she)施於(yu)1982年開業，該基(ji)地現(xian)有(you)面(mian)積(ji)9公頃(qing)。從(cong)早(zao)期的(de)批(pi)量生(sheng)產而(er)發展(zhan)成(cheng)為GSK制(zhi)藥供應鏈內的(de)新(xin)產(chan)品(pin)導入（NPI）基(ji)地。目前已逐(zhu)步發展(zhan)建(jian)立了新的(de)化(hua)學(xue)制(zhi)造實體(ti)（NCE），並(bing)提(ti)供更高價(jia)值(zhi)的(de)產(chan)品(pin)，例(li)如作(zuo)為(wei)小(xiao)批(pi)量的(de)活(huo)性(xing)化(hua)合(he)物。該地區(qu)目前擁有(you)壹個(ge)研發(fa)中試(shi)工(gong)廠(chang)，用於(yu)NCES的(de)開發和(he)放(fang)大(da)。以(yi)及三個(ge)生(sheng)產車(che)間，生(sheng)產的(de)13種(zhong)活(huo)性(xing)藥物(wu)成(cheng)分用於(yu)治療呼吸(xi)、腫(zhong)瘤學(xue)、過敏、抗病毒(du)和(he)神(shen)經疾病(bing)。Jurong廠(chang)區現(xian)有(you)490名(ming)員(yuan)工。